$TRDA insider trading
Over the last 12 months, Entrada Therapeutics insiders reported 2 buys totaling $1.6M and 21 sales totaling $15.1M across SEC Form 4 filings. 30% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $1.6M 2 events
- Sold · 12m
- $15.1M 21 events
- Events · 12m
- 23 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 30% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | MPM BIOVENTURES 2018, L.P.10% | ▼ Sale | 259,837 | $7.33 | $1.9M | -6.3% | 3 tranches · indirect |
| Sep 9, 2026 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 259,837 | $7.33 | $1.9M | -6.3% | 3 tranches · indirect |
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P.10% | ▼ Sale | 86,482 | $7.14 | $617K | -2% | 3 tranches · indirect |
| Sep 3, 2026 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 86,482 | $7.14 | $617K | -2% | 3 tranches · indirect |
| Aug 31, 2026 | MPM BIOVENTURES 2018, L.P.10% | ▼ Sale | 86,914 | $7.08 | $616K | -2% | 3 tranches · indirect |
| Aug 31, 2026 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 86,914 | $7.08 | $616K | -2% | 3 tranches · indirect |
| Aug 26, 2026 | MPM BioVentures 2014, L.P.10% | ▼ Sale | 62,714 | $7.36 | $462K | -1.4% | 3 tranches · indirect |
| Aug 26, 2026 | MPM BIOVENTURES 2018, L.P.10% | ▼ Sale | 62,714 | $7.36 | $462K | -1.4% | 3 tranches · indirect |
| Aug 10, 2026 | PARMAR KUSHD | ▼ Sale | 155,255 | $6.95 | $1.1M | -5.5% | 3 tranches · indirect |
| Aug 7, 2026 | 5AM Ventures V, L.P.10% | ▼ Sale | 62,811 | $6.88 | $432K | -2.2% | 2 tranches |
| Jul 31, 2026 | 5AM Ventures V, L.P.10% | ▼ Sale | 116,474 | $6.93 | $807K | -3.9% | 2 tranches |
| Jul 31, 2026 | PARMAR KUSHD·10% | ▼ Sale | 116,474 | $6.93 | $807K | -3.9% | 2 tranches · indirect |
| May 4, 2026 | Sethuraman NatarajanPresident, Research & Develop. · O | ▼ Sale | 25,907 | $15.39 | $399K | -10.7% | plan |
| May 4, 2026 | Dowden Nathan JPresident & COO · O | ▼ Sale | 15,000 | $15.33 | $230K | -7% | plan |
| Apr 1, 2026 | WENTWORTH KORY JAMESChief Financial Officer · O | ▼ Sale | 2,500 | $12.95 | $32K | -2.1% | plan |
| Mar 10, 2026 | Dowden Nathan JPresident & COO · O | ▼ Sale | 15,010 | $13.04 | $196K | -7% | plan · 2 tranches |
| Mar 10, 2026 | WENTWORTH KORY JAMESChief Financial Officer · O | ▼ Sale | 16,477 | $13.01 | $214K | -11.9% | plan · 2 tranches |
| Mar 4, 2026 | WENTWORTH KORY JAMESChief Financial Officer · O | ▼ Sale | 7,988 | $12.25 | $98K | -5.5% | plan |
| Nov 21, 2025 | WENTWORTH KORY JAMESChief Financial Officer · O | ▼ Sale | 8,910 | $9.98 | $89K | -7.5% | plan |
| Nov 20, 2025 | BAKER BROS. ADVISORS LP10% | ▲ Buy | 28,867 | $9.07 | $262K | +0.6% | 4 tranches · indirect |
| Nov 14, 2025 | PARMAR KUSHD·10% | ▼ Sale | 200,000 | $8.8 | $1.8M | -6.3% | indirect |
| Nov 14, 2025 | 5AM Ventures V, L.P.10% | ▼ Sale | 200,000 | $8.8 | $1.8M | -6.3% | — |
| Nov 12, 2025 | BAKER BROS. ADVISORS LP10% | ▲ Buy | 178,044 | $7.6 | $1.4M | +4% | 12 tranches · indirect |
Every $TRDA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Entrada Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TRDA feed.